Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: The german telaprevir early access program
H Wedemeyer, S Mauss, HW Busch, A Umgelter, P Buggisch, H Klinker, S Zeuzem, W Iraqi, A Hill, JM Läuffer, I Lonjon-Domanec, M Colombo · Zeitschrift für Gastroenterologie · 2013 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background and aims: HEP3002 is an ongoing, open-label, early access program of telaprevir in 16 countries, for patients with genotype 1 hepatitis C with severe fibrosis or compensated cirrhosis. Methods: Patients were treated with telaprevir, pegylated interferon-alpha and ribavirin (PR) for 12 weeks, followed by PR. Liver biopsy or non-invasive tests showing severe fibrosis (Metavir F3 or Ishak 3–4) or cirrhosis (Metavir F4 or Ishak 5–6) and platelet count >90 000/mm3 were required at entry. This interim (ITT) analysis included 16 week data from the first 93 patients in Germany. Results: For the 93 patients in…
